115 related articles for article (PubMed ID: 19735918)
1. Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: correlation with plaque composition.
Cyrus T; Ding T; Praticò D
Atherosclerosis; 2010 Feb; 208(2):376-81. PubMed ID: 19735918
[TBL] [Abstract][Full Text] [Related]
2. Reaction mechanisms of 15-hydroperoxyeicosatetraenoic acid catalyzed by human prostacyclin and thromboxane synthases.
Yeh HC; Tsai AL; Wang LH
Arch Biochem Biophys; 2007 May; 461(2):159-68. PubMed ID: 17459323
[TBL] [Abstract][Full Text] [Related]
3. Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium.
Kawka DW; Ouellet M; Hétu PO; Singer II; Riendeau D
Biochim Biophys Acta; 2007 Jan; 1771(1):45-54. PubMed ID: 17189713
[TBL] [Abstract][Full Text] [Related]
4. Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion.
Gabrielsen A; Qiu H; Bäck M; Hamberg M; Hemdahl AL; Agardh H; Folkersen L; Swedenborg J; Hedin U; Paulsson-Berne G; Haeggström JZ; Hansson GK
J Mol Med (Berl); 2010 Aug; 88(8):795-806. PubMed ID: 20383787
[TBL] [Abstract][Full Text] [Related]
5. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.
Cyrus T; Yao Y; Ding T; Dogné JM; Praticò D
Eur J Pharmacol; 2007 Apr; 561(1-3):105-11. PubMed ID: 17306791
[TBL] [Abstract][Full Text] [Related]
6. Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers.
Abe Y; Aly HH; Hiraga N; Imamura M; Wakita T; Shimotohno K; Chayama K; Hijikata M
Gastroenterology; 2013 Sep; 145(3):658-67.e11. PubMed ID: 23684750
[TBL] [Abstract][Full Text] [Related]
7. Altered prostanoid metabolism contributes to impaired angiogenesis in persistent pulmonary hypertension in a fetal lamb model.
Mahajan CN; Afolayan AJ; Eis A; Teng RJ; Konduri GG
Pediatr Res; 2015 Mar; 77(3):455-62. PubMed ID: 25521916
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
[TBL] [Abstract][Full Text] [Related]
9. The N-terminal membrane anchor domain of the membrane-bound prostacyclin synthase involved in the substrate presentation of the coupling reaction with cyclooxygenase.
Ruan KH; Deng H; Wu J; So SP
Arch Biochem Biophys; 2005 Mar; 435(2):372-81. PubMed ID: 15708381
[TBL] [Abstract][Full Text] [Related]
10. Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth.
Kajita S; Ruebel KH; Casey MB; Nakamura N; Lloyd RV
Mod Pathol; 2005 Feb; 18(2):221-7. PubMed ID: 15475935
[TBL] [Abstract][Full Text] [Related]
11. Thromboxane synthase and TP receptor mRNA in rat kidney and brain: effects of salt intake and ANG II.
Wilcox CS; Welch WJ
Am J Physiol Renal Physiol; 2003 Mar; 284(3):F525-31. PubMed ID: 12517736
[TBL] [Abstract][Full Text] [Related]
12. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.
Cherdon C; Rolin S; Hanson J; Ooms A; de Leval L; Drion P; Michiels C; Pirotte B; Masereel B; Sakalihassan N; Defraigne JO; Dogné JM
Prostaglandins Other Lipid Mediat; 2011 Apr; 94(3-4):124-32. PubMed ID: 21397034
[TBL] [Abstract][Full Text] [Related]
13. Thromboxane A2 Synthase and Thromboxane Receptor Deletion Reduces Ischaemia/Reperfusion-Evoked Inflammation, Apoptosis, Autophagy and Pyroptosis.
Chueh TH; Cheng YH; Chen KH; Chien CT
Thromb Haemost; 2020 Feb; 120(2):329-343. PubMed ID: 31785598
[TBL] [Abstract][Full Text] [Related]
14. Regulation of prostacyclin synthase expression and prostacyclin content in the pig endometrium.
Morawska E; Kaczmarek MM; Blitek A
Theriogenology; 2012 Dec; 78(9):2071-86. PubMed ID: 23043950
[TBL] [Abstract][Full Text] [Related]
15. Additive anti-atherogenic effect of thromboxane receptor antagonism with 12/15lipoxygenase gene disruption in apolipoprotein E-deficient mice.
Tang L; Ding T; Praticò D
Atherosclerosis; 2008 Aug; 199(2):265-70. PubMed ID: 18206890
[TBL] [Abstract][Full Text] [Related]
16. NADPH oxidase 1 mediates upregulation of thromboxane A2 synthase in human vascular smooth muscle cells: inhibition with iloprost.
Muzaffar S; Shukla N; Massey Y; Angelini GD; Jeremy JY
Eur J Pharmacol; 2011 May; 658(2-3):187-92. PubMed ID: 21371456
[TBL] [Abstract][Full Text] [Related]
17. Increased bone mass in adult prostacyclin-deficient mice.
Nakalekha C; Yokoyama C; Miura H; Alles N; Aoki K; Ohya K; Morita I
J Endocrinol; 2010 Feb; 204(2):125-33. PubMed ID: 19906840
[TBL] [Abstract][Full Text] [Related]
18. CD40 ligand-dependent tyrosine nitration of prostacyclin synthase in vivo.
Davis B; Zou MH
Circulation; 2005 Oct; 112(14):2184-92. PubMed ID: 16186418
[TBL] [Abstract][Full Text] [Related]
19. Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries.
Liu B; Luo W; Zhang Y; Li H; Zhu N; Huang D; Zhou Y
Exp Physiol; 2012 Feb; 97(2):277-89. PubMed ID: 22080487
[TBL] [Abstract][Full Text] [Related]
20. The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer.
Cathcart MC; Reynolds JV; O'Byrne KJ; Pidgeon GP
Biochim Biophys Acta; 2010 Apr; 1805(2):153-66. PubMed ID: 20122998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
